Can Scribe Therapeutics make one-dose LDL-C lowering a practical CRISPR frontier?
Find out how Scribe Therapeutics’ STX-1150 could reshape long-acting LDL-C lowering through CRISPR-based epigenetic silencing.
How Eli Lilly and Company is positioning VERVE-102 at the center of cardiovascular gene editing
Can Eli Lilly and Company’s VERVE-102 transform cholesterol treatment through one-time gene editing? Explore the risks, data, and implications.
Scribe Therapeutics brings specificity challenge into focus for CRISPR cardiometabolic drugs
CRISPR can lower cholesterol. The harder test is whether Scribe can make durability, precision, and scalability work in common disease.